RCELHIGH SIGNALFINANCIAL10-K

RCEL's balance sheet deteriorated dramatically with stockholders' equity swinging from positive $4.5M to negative $16.6M while current liabilities more than tripled to $62.7M.

The company has moved into negative equity territory, indicating accumulated losses now exceed invested capital, which raises serious concerns about financial stability and potential covenant violations. The massive increase in current liabilities combined with declining cash and receivables suggests potential liquidity stress and difficulty meeting short-term obligations.

Comparing 2026-02-12 vs 2025-02-13View on EDGAR →
FINANCIAL ANALYSIS

While RCEL showed operational improvement with operating losses narrowing 25% and operating cash flow improving 36%, the balance sheet tells a troubling story of financial deterioration. Current liabilities exploded 211% to $62.7M while current assets fell 38% to $35.5M, creating a dangerous liquidity mismatch, and the company's equity base turned negative by $16.6M. The dramatic reduction in capital expenditures by 89% suggests the company is conserving cash amid financial distress, making this a high-risk situation for investors despite the operational improvements.

FINANCIAL STATEMENT CHANGES
Provision for Credit Losses
P&L
+580%
-$5K$24K

Credit loss provisions surged 580% — management flagging significant deterioration in loan quality ahead.

Stockholders Equity
Balance Sheet
-470.1%
$4.5M-$16.6M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Current Liabilities
Balance Sheet
+210.9%
$20.2M$62.7M

Current liabilities surged 210.9% — significant near-term obligations; verify ability to meet short-term debt.

Capital Expenditure
Cash Flow
-89%
$9.2M$1.0M

Capex reduced 89% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Current Assets
Balance Sheet
-37.7%
$57.0M$35.5M

Current assets declined 37.7% — monitor working capital adequacy and short-term liquidity.

Operating Cash Flow
Cash Flow
+36.3%
-$48.9M-$31.2M

Operating cash flow surged 36.3% — exceptional cash generation, highest quality earnings signal.

Total Assets
Balance Sheet
-29.3%
$79.7M$56.4M

Total assets contracted 29.3% — asset sales, write-downs, or balance sheet optimization underway.

Cash & Equivalents
Balance Sheet
-27.1%
$14.1M$10.2M

Cash decreased 27.1% — monitor burn rate and upcoming capital needs.

Operating Income
P&L
+24.8%
-$56.6M-$42.5M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

Accounts Receivable
Balance Sheet
-22.9%
$11.8M$9.1M

Receivables declined — improved collection efficiency or conservative revenue recognition.

LANGUAGE CHANGES
NEW — 2026-02-12
PRIOR — 2025-02-13
ADDED
and global economies, respectively; changes in the legal or regulatory environments; the impact of a cybersecurity breach, terrorist attack or other geopolitical instability; and the impact of a pandemic or epidemic, or natural disaster.
BUSINESS OVERVIEW AVITA Medical is a leading therapeutic acute wound care company delivering transformative solutions designed to optimize wound healing, accelerate patient recovery, and improve clinical and economic outcomes across the continuum of acute wound management.
Our technologies address critical healing needs arising from burns, traumatic injuries and surgical repairs, through a portfolio of proprietary and complementary products that support wound bed preparation, definitive closure, and recovery.
Our current commercial portfolio includes RECELL ( RECELL ), and two complementary wound care products, PermeaDerm and Cohealyx , which together support a comprehensive standard of care for acute wounds.
At the forefront of our portfolio is RECELL, approved by the United States Food Drug Administration (the FDA ) for the treatment of thermal burn wounds and full-thickness skin defects.
+7 more — sign up free →
REMOVED
and global economies, respectively; changes in the legal or regulatory environments; the impact of a cybersecurity breach, terrorist attack or other geopolitical instability, pandemic or epidemic, or natural disaster; and future working capital, costs, productivity, business process, rationalization, investment (including rates), consulting, operational, financial, and capital projects and/or initiatives.
BUSINESS OVERVIEW AVITA Medical is a leading therapeutic acute wound care company delivering transformative solutions.
Our technologies are designed to optimize skin restoration procedures, effectively accelerating patient healing and recovery.
Our solutions improve the healing outcomes for patients with traumatic injuries and surgical repairs, addressing critical healing needs that arise from unpredictable and life-changing events.
Our offerings currently include our core technology platform, RECELL ( RECELL ), as well as PermeaDerm and Cohealyx , each designed to target acute wound care needs.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →